Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors

Molecular Cancer

Volumn 3, Issue , 2004, Pages

  Koul, Sanjay ^a   McKiernan, James M ^a   Narayan, Gopeshwar ^a   Houldsworth, Jane ^b   Bacik, Jennifer ^b   Dobrzynski, Deborah L ^b   Assaad, Adel M ^a   Mansukhani, Mahesh ^a   Reuter, Victor E ^b   Bosl, George J ^b   Chaganti, Raju S K ^b   Murty, Vundavalli V V S ^a  

^a Columbia University ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BRCA1 PROTEIN; CISPLATIN; FRAGILE HISTIDINE TRIAD PROTEIN; HISTONE DEACETYLASE INHIBITOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; DNA; FANCF PROTEIN, HUMAN; FANCONI ANEMIA GROUP F PROTEIN; HIC1 PROTEIN, MOUSE; HISTONE; KRUPPEL LIKE FACTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE; RASSF1 PROTEIN, HUMAN; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; DRUG SENSITIVITY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE INACTIVATION; GENETIC TRANSCRIPTION; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ACETYLATION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICENTER STUDY; PHYSIOLOGY; RETROSPECTIVE STUDY; TESTIS TUMOR; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CISPLATIN; COHORT STUDIES; DNA METHYLATION; DNA, NEOPLASM; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP F PROTEIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINOMA; HISTONES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; METHYLTRANSFERASES; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; TESTICULAR NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 2942617040     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-3-16     Document Type: Article

References (36)

1. Chaganti RS, Houldsworth J: Genetics and biology of adult human male germ cell tumors. Cancer Res 2000, 60:1475-82.
2. Motzer RJ, Amsterdam A, Prieto V, Sheinfeld J, Murty VV, Mazumdar M, Bosl GJ, Chaganti RS, Reuter VE: Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998, 159:133-8.
3. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 1997, 337:242-53.
4. Masters JR, Koberle B: Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 2003, 3:517-25.
5. Houldsworth J, Xiao H, Murty VV, Chen W, Ray B, Reuter VE, Bosl GJ, Chaganti RS: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998, 16:2345-9.
6. Rao PH, Houldsworth J, Palanisamy N, Murty VV, Reuter VE, Motzer RJ, Bosl GJ, Chaganti RS: Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 1998, 58:4260-3.
7. Mayer F, Gillis AJ, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LH: Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002, 62:2758-60.
8. Koul S, Houldsworth J, Mansukhani MM, Donadio A, McKiernan JM, Reuter VE, Bosl GJ, Chaganti RS, Murty VV: Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer 2002, 1:8.
9. Smiraglia DJ, Szymanska J, Kraggerud SM, Lothe RA, Peltomaki P, Plass C: Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene 2002, 21:3909-16.
10. Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F: Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 2003, 22:461-6.
11. Pegg AE, Dolan ME, Moschel RC: Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995, 51:167-223.
12. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-4.
13. Olopade OI, Wei M: FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell 2003, 3:417-20.
14. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003, 9:568-74.
15. Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT: Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 1988, 48:3019-24.
16. Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR: DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997, 70:551-5.
17. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-67.
18. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH: Role of P53 and MDM2 in treatment response of human germ cell tumors. Clin Oncol 2002, 20:1551-61.
19. Zamble DB, Jacks T, Lippard SJ: p53-Dependent and -independent responses to cisplatin mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A 1998, 95:6163-8.
20. Chresta CM, Masters JR, Hickman JA: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996, 56:1834-41.
21. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC: The biology of ovarian cancer. Semin Oncol 1998, 25:281-304.
22. Smith-Sorensen B, Lind GE, Skotheim RI, Fossa SD, Fodstad O, Stenwig AE, Jakobsen KS, Lothe RA: Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene 2002, 21:8878-84.
23. Pfeifer GP, Yoon JH, Liu L, Tommasi S, Wilczynski SP, Dammann R: Methylation of the RASSF1A gene in human cancers. Biol Chem 2002, 383:907-14.
24. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M, Watkins DN, Herman JG, Mankowski JL, Baylin SB: Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 2003, 33:197-202.
25. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-9.
26. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large Bcell lymphoma. J Natl Cancer Inst 2002, 94:26-32.
27. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B: Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001, 92:123-9.
28. Sun SY, Lotan R: Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002, 41:41-55.
29. Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997, 386:153-61.
30. Nyce J: Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989, 49:5829-36.
31. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003, 4:75-85.
32. Zamble DB, Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995, 20:435-9.
33. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A: HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 1994, 91:10394-8.
34. Zamble DB, Mikata Y, Eng CH, Sandman KE, Lippard SJ: Testis-specific HMG-domain protein alters the responses of cells to cisplatin. J Inorg Biochem 2002, 91:451-62.
35. Koberle B, Masters JR, Hartley JA, Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9:273-6.
36. Bala S, Oliver H, Renault B, Montgomery K, Dutta S, Rao PH, Houldsworth J, Kucherlapati R, Wang X, Chaganti RS, Murty VV: Genetic analysis of the APAF1 gene in male germ cell tumors. Genes Chromosomes Cancer 2000, 28:258-68.